Efficacy of liraglutide 3 mig therapy in obesity and associated diseases
Obesity is a chronic disease associated with cardiometabolic risk factors, primarily cardiovascular diseases and type 2 diabetes mellitus. In 2016,Russiaregistered a new drug for treating obese patients liraglutide 3.0 mg, which is an analogue of human glucagon-like peptide-1. Given the urgency of t...
Main Authors: | K. A. Komshilova, E. A. Troshina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2018-03-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/2338 |
Similar Items
-
EARLY EXPERIENCE OF GPP-1 LIRAGLUTIDE 3.0 MG ANALOGUE IN RUSSIA AND ITS EFFECT ON METABOLIC RISK FACTORS IN OBESITY PATIENTS
by: K. A. Komshilova, et al.
Published: (2017-12-01) -
Prediction of early response to liraglutide therapy in patients with obesity
by: Oksana V. Logvinova, et al.
Published: (2020-06-01) -
Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01) -
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
by: Christiane Lundegaard Haase, et al.
Published: (2021-08-01) -
Short-term monotherapy with Liraglutide for weight management: A case study
by: Feras Almarshad
Published: (2019-01-01)